ARS Pharmaceuticals Inc
SPRY16.930USD
-0.520-2.98%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.66BMarktkapitalisierung
207.72KGV TTM
mehr Informationen über ARS Pharmaceuticals Inc Unternehmen
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Unternehmensinformationen
BörsenkürzelSPRY
Name des UnternehmensARS Pharmaceuticals Inc
IPO-datumDec 04, 2020
Gegründet am2016
CEOMr. Richard E. Lowenthal
Anzahl der mitarbeiter155
WertpapierartOrdinary Share
GeschäftsjahresendeDec 04
Addresse11682 El Camino Real, Suite 120
StadtSAN DIEGO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92130
Telefon18587719307
Websitehttps://ars-pharma.com/
BörsenkürzelSPRY
IPO-datumDec 04, 2020
Gegründet am2016
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Jun 2
Aktualisiert: Mon, Jun 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
20.71%
Hedge Fund
19.64%
Venture Capital
15.20%
Investment Advisor
13.88%
Individual Investor
12.16%
Private Equity
8.44%
Corporation
4.91%
Research Firm
2.18%
Pension Fund
0.27%
Other
2.62%
Institutionelle Beteiligung
Aktualisiert: 11 hours ago
Aktualisiert: 11 hours ago
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
361
95.98M
97.72%
-8.84M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
2023Q1
271
88.79M
98.08%
+1.91M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
10.86M
11.06%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
10.51M
10.71%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
8.29M
8.44%
--
--
Mar 31, 2025
Lowenthal (Richard E)
6.83M
6.95%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.91%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.66%
-556.66K
-10.85%
Mar 31, 2025
SR One Capital Management, LP
4.01M
4.09%
--
--
Mar 31, 2025
AllianceBernstein L.P.
3.92M
3.99%
+42.07K
+1.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.88M
3.95%
-275.85K
-6.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.48M
3.54%
+23.34K
+0.68%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
First Trust Small Cap Growth AlphaDEX Fund
0.6%
Janus Henderson Small Cap Growth Alpha ETF
0.39%
First Trust Small Cap Core Alphadex Fund
0.29%
SPDR S&P Biotech ETF
0.24%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
First Trust Multicap Growth Alphadex Fund
0.11%
Principal U.S. Small-Cap ETF
0.11%
Mehr Anzeigen
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.6%
Janus Henderson Small Cap Growth Alpha ETF
Anteil0.39%
First Trust Small Cap Core Alphadex Fund
Anteil0.29%
SPDR S&P Biotech ETF
Anteil0.24%
iShares Micro-Cap ETF
Anteil0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.16%
ProShares Ultra Nasdaq Biotechnology
Anteil0.14%
Invesco Nasdaq Biotechnology ETF
Anteil0.14%
First Trust Multicap Growth Alphadex Fund
Anteil0.11%
Principal U.S. Small-Cap ETF
Anteil0.11%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
